newsfilter
← Latest News
GlobeNewswire·

Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

- Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end - Presented new analysis of OLC data at American Society of Nephrology (ASN) which demonstrates that OLC